TIME magazine has named women's health specialist Sprout Pharmaceuticals among 10 organisations globally shaping the future of health and life sciences.

This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi.

In December 2025, the US Food and Drug Administration (FDA) approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion.

TIME evaluated companies based on impact, innovation, ambition, and success, selecting just 10 companies in health and life sciences as industry leaders.